Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

On-Demand Webcast
Moderator

Richard R. Furman, MD
Weill Cornell Medicine
New York, New York

Faculty

Steven P. Treon, MD, PhD, FACP, FRCP
Dana-Farber Cancer Institute
Harvard University
Boston, Massachusetts

Target Audience

This activity is intended for hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.

Overview

Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma that comprises 1–2% of all non-Hodgkin lymphomas (NHLs). While WM is considered an indolent NHL, risk stratification based on patient- and disease-specific characteristics is critical for prognosis, and those patients classified as high-risk have a relative 5-year survival rate of only 36%. The indolent nature of WM, coupled with its pathophysiologic and phenotypic characteristics that resemble those of both other B-cell lymphomas and multiple myeloma (MM), presents a challenge in differential diagnosis, necessitating a thorough understanding of the signs, symptoms, and diagnostic criteria that distinguish WM from these overlapping disorders. Similarly, WM treatments are largely adapted from other B-cell lymphomas and MM, including chemoimmunotherapy with anti-CD20 antibodies and proteasome inhibitors; the Bruton tyrosine kinase (BTK) inhibitor ibrutinib remains the only agent with an FDA-approved indication for WM. Given its rarity, there are comparatively few large-scale phase 3 trials in patients with WM; as a result, WM treatment guidelines and best practices have developed largely in the absence of substantial clinical trial evidence. Thus, real-world data provides a particularly valuable source of information for evaluating the comparative benefits, toxicities, and costs of therapeutic approaches to WM, complementing available clinical trial data and the latest guideline recommendations.

This webcast aims to fill the gaps surrounding the WM disease state and its evolving therapeutic armamentarium in order to accurately identify and stratify patients with WM and make informed decisions surrounding treatment selection, sequencing, and monitoring.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Discuss the pathophysiologic features of WM as they relate to differential diagnosis, risk stratification, and prognostic biomarkers for optimal patient identification and treatment
  2. Evaluate the clinical data surrounding current and emerging WM therapies with respect to their mechanisms of action, efficacy, safety, and indications
  3. Integrate current guidelines, available clinical trial data, and real-world evidence into individualized strategies for WM treatment selection, sequencing, and monitoring     

Release Date: December 31, 2019

Expiration Date: December 31, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

Supported by and educational grant from: Janssen Biotech.

Accreditation

 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

PHYSICIANS

NACCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.

CPE

This knowledge-based activity (JA0006201-9999-20-044-H01-P) is approved for 1.0 contact hour (0.1 CEU) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Richard R. Furman, MD, Steven P. Treon, MD, PhD, FACP, FRCP;  and Chris Bolwell, Lara Gray, and Griselda Zuccarino-Catania Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Richard R. Furman, MD, reports that he is a consultant Abbvie, Acerta, AstraZeneca, Beigene, Genentech, Incyte, Janssen, Loxo Oncology, Oncotracker, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem; has received grant or research support from Acerta, AstraZeneca, and TG Therapeutics; and has received other financial support from Incyte.

Steven P. Treon, MD, PhD, FACP, FRCP, reports that he is a consultant for BeiGene, Inc. and Janssen Pharmaceuticals.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

Lara Gray disclosed no relevant financial relationships with any commercial interests.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.